Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans

Cardiovascular Drugs and Therapy

Volumn 10, Issue 6, 1997, Pages 717-725

  Sütsch, Gabor ^a   Bertel, Osmund ^a   Kiowski, Wolfgang ^a,b  

^a TRIEMLI HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Endothelin 1; ET(A B) receptor antagonism; Hemodynamics; Human heart failure

Indexed keywords

BOSENTAN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; NEUROHORMONE;

ADULT; AGED; ARTICLE; BLOOD VESSEL TONE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG TOLERABILITY; FEMALE; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CAPILLARY PRESSURE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; BLOOD PRESSURE; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; SULFONAMIDES; TIME FACTORS; VASCULAR RESISTANCE;

EID: 0030891727     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00053029     Document Type: Article

References (46)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
2. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1989;332:411-415.
3. Vane JR, Änggard EE, Botting RM. Regulatory functions of the endothelium. N Engl J Med 1990;323:27-36.
4. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
5. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989;2:997-1000.
6. Kiowski W, Linder L, Stoschitzky K, et al. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogeneously administered endothelin-1 in clinically healthy smokers. Circulation 1994;90:27-34.
7. Drexler H, Hayoz D, Münzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992;69: 1596-1601.
8. Linder L, Kiowski W, Bühler FR, Lüscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990;81:1762-1767.
9. Creager MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990;86:228-234.
10. Kiowski W, Lüscher TF, Linder L, Bühler FR. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991;83:469-475.
11. Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988;238:249-252.
12. Ito H, Hirata Y, Hiroe M, et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991;69:209-215.
13. Kaddoura S, Firth JD, Boheler KR, Sugden PH, Poole-Wilson PA. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Circulation 1996; 93:2068-2079.
14. Koyama H, Tabata T, Nishzawa Y, Inoue T, Morii H, Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet 1989;1:991-992.
15. Kohno M, Yasunari K, Murakawa K, et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990;88:614-618.
16. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739.
17. Lerman A, Holmes DR, Bell MR, Garratt KN, Nishimura RA, Burnett JC. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995;92:2426-2431.
18. Matsuyama K, Yasue H, Okumura K, et al. Increased plasma level of endothelin-1-like immunoreactivity during coronary spasm in patients with coronary spastic angina. Am J Cardiol 1991;68:991-995.
19. Stewart EU, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 1992;85:510-517.
20. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994;89: 1580-1586.
21. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994;89:1573-1579.
22. Pacher R, Stanek B, Hülsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-641.
23. Lerman A, Hildebrand FLJ, Aarhus LL, Burnett JCJ. Endothelin has biological actions at pathophysiological concentrations. Circulation 1991;83:1808-1814.
24. Ahlborg G, Ottoson-Seeberger A, Hemsen A, Lundberg JM. Big ET-1 infusion in man causes renal ET-1 release, renal and splanchnic vasoconstriction, and increased mean arterial blood pressure. Cardiovasc Res 1994;28:1559-1563.
25. Clozel M, Breu V, Burri K, et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993;365:759-761.
26. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344: 852-854.
27. Teerlink JR, Carteaux JP, Sprecher U, Löffler BM, Clozel M, Clozel JP. Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am J Physiol 1995; 268:H432-H440.
28. Clozel M, Gray GA, Breu V, Löffler BM, Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992;186:867-873.
29. Takayanagi R, Kitazumi K, Takasaki C, et al. Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. FEBS Lett 1991;282: 103-106.
30. Kiowski W, Sütsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-736.
31. Cody R, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-509.
32. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992;267:16066-16068.
33. Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in DOCA-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994;24:183-188.
34. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994;199: 1461-1465.
35. Teerlink JR, Löffler BM, Hess P, Maire JP, Clozel M, Clozel JP. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 1994;90:2510-2518.
36. Ichikawa KI, Hidai C, Okuda C, et al. Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium. J Am Coll Cardiol 1996;27:1286-1291.
37. Bakris GL, Re RN. Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol 1993;246:F937-F942.
38. Fujisaki H, Ito H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995;96:1059-1065.
39. Sung CP, Arleth AJ, Storer BL, Ohlstein EH. Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther 1994;271:429-437.
40. Hirata Y, Kanno K, Eguchi S, Kano H. Effect of an ATI receptor antagonist (CV-11974) on angiotensin II-induced cardiomyocyte hypertrophy in vitro. Blood Press 1994; 5(Suppl):84-88.
41. Hatakeyama H, Miyamori I, Yamagishi S, Takeda Y, Takeda R, Yamamoto H. Angiotensin II up-regulates the expression of type A endothelin receptor in human vascular smooth muscle cells. Biochem Mol Biol Int 1994;34: 127-134.
42. Chen L, McNeill JR, Wilson TW, Gopalakrishnan V. Heterogeneity in vascular smooth muscle responsiveness to angiotensin II. Role of endothelin. Hypertension 1995;26: 83-88.
43. Kawaguchi H, Sawa H, Yasuda H. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol 1990; 22:839-842.
44. Yang ZH, Richard V, von Segesser L, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation 1990;82:188-195.
45. Yoshida H, Nakamura M. Inhibition by angiotensin converting enzyme inhibitors of endothelin secretion from cultured human endothelial cells. Life Sci 1992;50:PL195-PL200.
46. Cannan CR, Burnett JC, Lerman A. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. Circulation 1996;93: 646-651.